Your browser doesn't support javascript.
loading
Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.
Whelan, Adam O; Flick-Smith, Helen C; Homan, Jane; Shen, Zu T; Carpenter, Zoe; Khoshkenar, Payam; Abraham, Ambily; Walker, Nicola J; Levitz, Stuart M; Ostroff, Gary R; Oyston, Petra C F.
Afiliación
  • Whelan AO; CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
  • Flick-Smith HC; CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
  • Homan J; ioGenetics LLC, Madison, WI, United States of America.
  • Shen ZT; University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
  • Carpenter Z; CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
  • Khoshkenar P; University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
  • Abraham A; University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
  • Walker NJ; CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
  • Levitz SM; University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
  • Ostroff GR; University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
  • Oyston PCF; CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
PLoS One ; 13(10): e0200213, 2018.
Article en En | MEDLINE | ID: mdl-30296254
ABSTRACT
Francisella tularensis is an intracellular pathogen causing the disease tularemia, and an organism of concern to biodefence. There is no licensed vaccine available. Subunit approaches have failed to induce protection, which requires both humoral and cellular immune memory responses, and have been hampered by a lack of understanding as to which antigens are immunoprotective. We undertook a preliminary in silico analysis to identify candidate protein antigens. These antigens were then recombinantly expressed and encapsulated into glucan particles (GPs), purified Saccharomyces cerevisiae cell walls composed primarily of ß-1,3-glucans. Immunological profiling in the mouse was used to down-selection to seven lead antigens FTT1043 (Mip), IglC, FTT0814, FTT0438, FTT0071 (GltA), FTT0289, FTT0890 (PilA) prior to transitioning their evaluation to a Fischer 344 rat model for efficacy evaluation. F344 rats were vaccinated with the GP protein antigens co-delivered with GP-loaded with Francisella LPS. Measurement of cell mediated immune responses and computational epitope analysis allowed down-selection to three promising candidates FTT0438, FTT1043 and FTT0814. Of these, a GP vaccine delivering Francisella LPS and the FTT0814 protein was able to induce protection in rats against an aerosol challenge of F. tularensis SchuS4, and reduced organ colonisation and clinical signs below that which immunisation with a GP-LPS alone vaccine provided. This is the first report of a protein supplementing protection induced by LPS in a Francisella vaccine. This paves the way for developing an effective, safe subunit vaccine for the prevention of inhalational tularemia, and validates the GP platform for vaccine delivery where complex immune responses are required for prevention of infections by intracellular pathogens.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tularemia / Vacunas Bacterianas / Francisella tularensis / Glucanos Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tularemia / Vacunas Bacterianas / Francisella tularensis / Glucanos Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido